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Abstract
This communication reports the effect of alphaxalone on motor somatosensory evoked potential (SEPs) in a
rhesus macaque. The animal was deeply anaesthetised with an infusion of ketamine, medetomidine, mid-
azolam and alfentanil. The median nerve was stimulated, and SEPs were recorded from the motor cortex.
The successive administration of three doses of alphaxalone (0.5, 1 and 2 mg/kg) induced an increase of the
latency time and a decrease of the amplitude of the SEPs. However, the structure of the waveforms was
conserved, and hence alphaxalone might represent a suitable general anaesthetic option in neuroscience
research as well as veterinary or human medicine.
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Introduction
The principal form of communication between neurons
is the action potential generated by ion transport across
the neurone cell membrane. Somatosensory evoked
potentials (SEPs) are action potentials produced when
one of the peripheral sensory receptors or an afferent
nerve of the somatosensory system (e.g. touch, pain,
kinaesthesia) is stimulated over their resting threshold.
SEPs can be recorded at the level of the contralateral
somatosensory cortex and are an indicator of the integ-
rity of the various components of the afferent somato-
sensory pathway.1,2 SEPs are widely used in the clinical
setting during spinal surgery, such as the correction of
scoliosis, as well as in research for pain and neuroplas-
ticity studies.1–3 Anaesthetics can affect amplitude and
latency in a dose-dependent manner, particularly halo-
genated agents, which produce the most interference
with SEPs.4 As a result, injectable agents such as keta-
mine and a2-agonists are preferred.
3–5 Alphaxalone
(3a-hydroxy-5a-pregnane-11,20-dione) is a short-
acting neurosteroid anaesthetic with no
cumulative effect.6 This communication reports the
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One adult female rhesus macaque (four years old, body
weight 7 kg) was involved in this study. The animal was
pair-housed in indoor pens with a solid floor (minimum
of 4.40 m2) and windows, allowing a view of the other
pens and the corridors. Enrichment devices and sub-
strate for foraging were provided.
Anaesthesia procedure
To conduct motor SEPs recordings, the primate was
sedated with 10mg/kg intramuscular ketamine
(Narketan 10, 100mg/mL; Vetoquinol UK Ltd,
Towcester, UK), and anaesthesia was induced with
slow intravenous administration of 6mg/kg propofol
(Fresenius Propoven, 1%; Fresenius Kabi Ltd,
Runcorn, UK) to allow endotracheal intubation.
Anaesthesia was maintained with intravenous infusion
of 6–8.6mg/kg/h ketamine, 0.2–0.6 lg/kg/min alfenta-
nil (Alfentanil, 500 lg/mL solution for injection;
Hameln Pharmaceuticals, Gloucester, UK) and 1–
3.56 lg/kg/h of medetomidine (DomitorVR 1mg/mL
solution for injection; Vetoquinol UK Ltd). The
animal was connected to a circle breathing system
(Clear-FloTM; Intersurgical Ltd, Wokingham, UK)
and the lungs were mechanically ventilated (Merlin
Small Animal Ventilator; Vetronic Services Ltd,
Abbotskerswell, UK). Physiological parameters (elec-
trocardiogram, SpO2, invasive blood pressure, rectal
temperature, EtCO2, gas analyser) were constantly
monitored with a Vitalogik 4500 monitoring system
(Charter-Kontron Ltd, Milton Keynes, UK).
SEPs recording protocol
While the animal was anaesthetised, two external elec-
trodes (3MTM Red DotTM Repositionable Monitoring
Electrode 2660-3) were placed over the median nerve
route to stimulate it. The intensity of stimulation was
equivalent to two-and-a-half times the motor thresh-
old. This level of stimulation is usually optimal to acti-
vate all group I and II afferents without causing pain.
An epidural recording of the SEPs resulting from
median nerve stimulation was performed by the appo-
sition of a dipolar ball electrode on the dura of the
primary motor cortex (M1) and somatosensory cortex
(S1) regions (gain 50 K, bandpass 0.5 Hz–2 KHz, sam-
pling rate 5KHz). Stimulus markers and SEPs were
sampled using a micro1401 interface and Spike2 soft-
ware (Cambridge Electronic Design, Cambridge, UK).
Alphaxalone administration
After baseline waveform recording for three minutes,
three intravenous boluses of alphaxalone (Alfaxan,
10mg/ml solution for injection for dogs and cats;
Jurox UK Ltd, Crawley, UK) at 0.5, 1 and 2mg/kg
were successively administered. After the administra-
tion of each incremental dose, SEPs were recorded
for a period of 1000 seconds, and a washout period
of five minutes was allowed for the waveform param-
eters to return to baseline.
Waveforms analysis
From the recorded SEP waveforms, two parameters
were analysed: the latency representing the time from
the stimulation to the first peak and the amplitude of
this peak. The Friedman test was used to compare the
P1 amplitudes and latencies between the three alphax-
alone doses. Statistical analysis was performed with
GraphPad version 7.0d (GraphPad Software LLC, La
Jolla, CA). A p-value of <0.05 was considered statisti-
cally significant.
Results
The intravenous administration of each bolus of
alphaxalone did not modify the primate’s heart rate
and blood pressure. However, after the administration
of each bolus, a significant modification of P1 ampli-
tude (p<0.0001) and latency (p<0.0001) compared to
baseline was observed (Figure 1).
Figure 1. Influence of alphaxalone on motor SEPs wave-
form. The waveforms for the figure were obtained by
merging all the individual waveforms recorded for each
alphaxalone concentration. The arrow ( ) highlights the
peak corresponding to the stimuli. The latency and ampli-
tude were, respectively: at baseline, 8.60 ms and 16.3
0.5 lV; at 0.5 mg/kg, 9.10.1 ms and 10.10.7 lV; at 1 mg/
kg, 9.40.1 ms and 11.10.5 lV; at 2 mg/kg, 9.50.1 ms
and 11.50.4 lV.
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Discussion
This report shows that alphaxalone influences the
amplitude and latency of motor SEPs, but the recorded
waveform was conserved and can be easily analysed at
doses at least up to 2mg/kg. Interestingly, the ampli-
tude of the SEPs recorded increased with successive
doses, and hence habituation of the central nervous
system to the effects of alphaxalone cannot be ruled
out. Also, the other components of the balanced anaes-
thetic regimen administered when recording baseline
responses may have influenced the SEPs. The use of
ketamine, midazolam and opioids has been described
and used to record motor SEPs in rhesus macaque.7
Alphaxalone is a general anaesthetic acting at the
GABAa receptor, resulting in the hyperpolarisation
of the neuron and inhibition of action potentials.8
This anaesthetic was widely investigated in dogs and
cats, and it has wide safety margins in these species
with hypoventilation and apnoea as the main compli-
cations.9,10 The use of alphaxalone in combination with
other anaesthetics to immobilise macaques has also
been described, where the highest dose of 2mg/kg
administered in this report was similar to those previ-
ously reported.11,12 Currently, alphaxalone is only
available for veterinary use, but a formulation was pre-
viously available for human anaesthesia known as
Althesin. The use of Althesin was considered suitable
for human neuroanaesthesia.13,14 A new formulation of
alphaxalone is currently entering Phase III clinical
trials in humans (https://adisinsight.springer.com/
trials/700292315).
In conclusion, despite the alteration of motor SEPs
parameters, the use of alphaxalone may be a useful
agent in neuroscience research and could represent an
alternative to ketamine which is becoming subject to
greater access control worldwide.15 However, further
work is required to establish an optimal anaesthesia
regimen, dependent on the medical or scientific
objectives.
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Resume
Cette communication rapporte l’effet de l’alfaxalone sur le potentiel evoque moteur somesthesique (PES) du
macaque rhesus. L’animal a ete profondement anesthesie par une perfusion de ketamine, de medetomidine,
de midazolam et d’alfentanil. Le nerf median a ete stimule et les PES ont ete enregistres à partir du cortex
moteur. L’administration successive de trois doses d’alphaxalone (0.5, 1 et 2 mg/kg) a induit une augmen-
tation du temps de latence et une diminution de l’amplitude des PES. Toutefois, la structure des formes
d’onde a ete conservee et, par consequent, l’alphaxalone pourrait representer une option anesthesique
generale appropriee pour la recherche en neurosciences ainsi que la medecine veterinaire ou humaine.
Abstract
Diese Mitteilung informiert über die Wirkung von Alfaxalon auf motorisch-somatosensorisch evozierte
Potenziale (SEP) bei einem Rhesusaffen. Das Tier wurde mit einer Infusion mit Ketamin, Medetomidin,
Midazolam und Alfentanil tief narkotisiert. Der Nervus medianus wurde stimuliert und SEP aus dem motor-
ischen Kortex aufgezeichnet. Die sukzessive Verabreichung von drei Dosen Alfaxalon (0,5, 1 und 2 mg/kg)
induzierte eine Verl€angerung der Latenzzeit und eine Abnahme der Amplitude der SEP. Die Struktur der
Wellenformen blieb jedoch erhalten, so dass Alfaxalon eine geeignete Option für die Allgemeinan€asthesie in
der neurowissenschaftlichen Forschung sowie in der Veterin€ar- oder Humanmedizin darstellen k€onnte.
Resumen
Este informe refleja el efecto de alfaxalona sobre potenciales evocados somatosensitivos (SEP) motores en
macacos Rhesus. El animal fue anestesiado mediante una infusion de ketamina, medetomidina, midazolam y
alfentanil. El nervio mediano fue estimulado y se registraron SEP de la corteza motora. La administracion
sucesiva de tres dosis de alfaxolona (0,5, 1 y 2 mg.kg1) indujo un aumento del tiempo de latencia y una
disminucion de la amplitud de los SEP. Sin embargo, la estructura de la formacion de ondas fue conservada y,
por tanto, la alfaxalona puede representar una opcion de anestesia general adecuada en la investigacion de
neurociencia ası como en la medicina veterinaria o humana.
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